mob peptides semaglutide Semaglutide | Peak Biosciences

Body composition support: associated with a better balance between lean mass and fat, supporting body recomposition

No liver toxicity safety signal was identified

Participants were randomized to semaglutide 2.4 mg per week or placebo

Semaglutide and tirzepatide represent the two most-studied GLP-1 therapies available through PlexusDx

#DiabetesCare #PrecisionMedicine #MetabolicHealth #LowerTheDose #HealthcareInnovation To view or add a comment, sign in In our recent publication in Diabetes, Obesity and Metabolism, together with Professors Kokkinos and le Roux, we articulate a perspective grounded in robust scientific evidence, yet one that is rarely expressed with candor in the public scientific discourse: that, as with any other chronic disease, pharmacotherapy should constitute the central pillar in the treatment of obesity, while other approaches retain an important but complementary role